co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Company profile
Ticker
CODX
Exchange
Website
CEO
Dwight Egan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
DNA Logix, Inc. • Idaho Molecular, Inc. • Advanced Conceptions, Inc. ...
CODX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
15 Mar 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
31 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results
10 Aug 23
DEF 14A
Definitive proxy
20 Jul 23
8-K
Departure of Directors or Certain Officers
16 May 23
Transcripts
CODX
Earnings call transcript
2023 Q4
14 Mar 24
CODX
Earnings call transcript
2023 Q3
9 Nov 23
CODX
Earnings call transcript
2023 Q2
10 Aug 23
CODX
Earnings call transcript
2023 Q1
11 May 23
CODX
Earnings call transcript
2022 Q4
16 Mar 23
CODX
Earnings call transcript
2022 Q3
11 Nov 22
CODX
Earnings call transcript
2022 Q2
11 Aug 22
CODX
Earnings call transcript
2022 Q1
13 May 22
CODX
Earnings call transcript
2021 Q4
24 Mar 22
CODX
Earnings call transcript
2021 Q3
12 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 10.24 mm | 10.24 mm | 10.24 mm | 10.24 mm | 10.24 mm | 10.24 mm |
Cash burn (monthly) | 1.20 mm | 5.94 mm | 2.98 mm | 4.75 mm | 2.20 mm | 1.78 mm |
Cash used (since last report) | 8.24 mm | 40.87 mm | 20.50 mm | 32.69 mm | 15.13 mm | 12.22 mm |
Cash remaining | 2.00 mm | -30.63 mm | -10.26 mm | -22.45 mm | -4.89 mm | -1.98 mm |
Runway (months of cash) | 1.7 | -5.2 | -3.4 | -4.7 | -2.2 | -1.1 |
Institutional ownership, Q2 2023
14.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 43 |
Opened positions | 7 |
Closed positions | 18 |
Increased positions | 7 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 4.14 bn |
Total shares | 4.39 mm |
Total puts | 42.10 k |
Total calls | 40.70 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.78 mm | $1.98 bn |
Renaissance Technologies | 653.70 k | $726.00 k |
BLK Blackrock | 506.51 k | $562.23 mm |
Geode Capital Management | 302.16 k | $335.39 mm |
Bridgeway Capital Management | 272.90 k | $302.92 mm |
BK Bank Of New York Mellon | 145.62 k | $161.64 mm |
STT State Street | 100.65 k | $111.72 mm |
First Trust Advisors | 81.18 k | $90.11 mm |
MNGPF Man | 74.10 k | $82.25 mm |
Koss-Olinger Consulting | 65.07 k | $72.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Nov 23 | Brian Lee Brown | Common Stock | Sale back to company | Dispose D | No | No | 1.26 | 36,125 | 45.52 k | 213,220 |
23 Nov 23 | Brian Lee Brown | Common Stock | Grant | Acquire A | No | No | 0 | 118,332 | 0.00 | 249,345 |
23 Nov 23 | Brian Lee Brown | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 118,332 | 0.00 | 403,334 |
23 Nov 23 | Dwight H Egan | Common Stock | Sale back to company | Dispose D | No | No | 1.26 | 46,047 | 58.02 k | 270,881 |
23 Nov 23 | Dwight H Egan | Common Stock | Grant | Acquire A | No | No | 0 | 150,834 | 0.00 | 316,928 |
23 Nov 23 | Dwight H Egan | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 150,834 | 0.00 | 490,833 |
23 Nov 23 | Ted Murphy | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 97,500 |
23 Nov 23 | Ted Murphy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 120,000 |
23 Nov 23 | James B Nelson | Common Stock | Grant | Acquire A | No | No | 0 | 30,000 | 0.00 | 85,000 |
23 Nov 23 | James B Nelson | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 30,000 | 0.00 | 120,000 |
News
Co-Diagnostics, Inc. Appoints Richard Abbott As President, Concurrent With The Co Naming David Nielsen To Be Its Chief Operations Officer
4 Apr 24
Peering Into Co-Diagnostics's Recent Short Interest
2 Apr 24
HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2.5
15 Mar 24
Co-Diagnostics: Q4 Earnings Insights
14 Mar 24
Earnings Scheduled For March 14, 2024
14 Mar 24
Press releases
Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
25 Apr 24
Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan
24 Apr 24
Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event
12 Apr 24
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
4 Apr 24
Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions
4 Apr 24